补体系统，先天免疫“加油站”
补体级联中药物干预的目标及其相关抑制剂
http://dx.doi.org/10.1016/j.smim.2016.06.001
补体激活及其相关疾病
抗补体药物及其临床进展
https://doi.org/10.1016/j.molimm.2019.07.030
产品特色
产品齐全：全面覆盖热门补体因子靶点
多种属覆盖：人，小鼠，大鼠，食蟹猴...
广泛的应用场景：免疫、抗体筛选及表征等
高生物活性经结合抗体结合验证
严格质控流程，高品质，高批间一致性
免费共享Protocol
产品列表
验证数据
The purity of Human Complement C5a, Fc Tag (Cat. No. C5A-H525a) is more than 90% and the molecular weight of this protein is around 80-90 kDa verified by SEC-MALS.
The purity of Cynomolgus Complement C3, His Tag (Cat. No. CO3-C52H5) is more than 95% and the molecular weight of this protein is around 168-205 kDa verified by SEC-MALS.
Immobilized Human Complement C5, His Tag (Cat. No. CO5-H52Ha) at 2 μg/mL (100 μL/well) can bind Eculizumab Biosimilar with a linear range of 0.1-4 ng/mL (Routinely tested).
Protocol
Immobilized Human Complement C5a, His Tag (Cat. No. C5A-H51H9) at 5 μg/mL (100 μL/well) can bind Monoclonal Anti-Human C5a Human Antibody, Human IgG1 with a linear range of 0.1-4 ng/ml (QC tested).
Protocol
Human Complement C5a, Tag Free (Cat. No. C5A-H5116) induce N-acetyl-β-D-glucosaminidase release from differentiated U937 cells. The ED50 for this effect is 0.215-0.323 μg/mL (Routinely tested).
Protocol
相关阅读
参考文献
- 1. King B C, Blom A M. Intracellular complement: Evidence, definitions, controversies, and solutions[J]. Immunological Reviews, 2023, 313(1): 104-119.
- 2. Zelek W M, Xie L, Morgan B P, et al. Compendium of current complement therapeutics[J]. Molecular immunology, 2019, 114: 341-352..
- 3. Lubbers R, Van Essen M F, Van Kooten C, et al. Production of complement components by cells of the immune system[J]. Clinical & Experimental Immunology, 2017, 188(2): 183-194.
- 4. Ricklin D, Lambris J D. New milestones ahead in complement-targeted therapy[C]//Seminars in immunology. Academic Press, 2016, 28(3): 208-222.
- 背景
- 产品特色
- 产品列表
- 验证数据
- 参考文献